|
|
| (181 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | + | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| | + | *'''[[Clinical guidelines and advice]]''' |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Respiration mgmt]]''' |
| | + | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | + | |
| | + | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | + | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | + | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | *
| |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32311462|t=2020. On the molecular determinants of the SARS-CoV-2 attack |pdf=|usr=}}
| |
| − | {{tp|p=32129843|t=ä. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients |pdf=|usr=}}
| |
| − | {{tp|p=32129842|t=ä. A glimpse into the origins of genetic diversity in SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32229288|t=ä. Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32220422|t=2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32271376|t=ä. Factors associated with prolonged viral RNA shedding in patients with COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| | + | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32339487|t=2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China |pdf=|usr=}}
| |
| − | {{tp|p=32333860|t=2020. Presepsin in risk stratification of SARS-CoV-2 patients |pdf=|usr=}}
| |
| − | {{tp|p=32161940|t=ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32280952|t=ä. Good IgA bad IgG in SARS-CoV-2 infection?|pdf=|usr=}}
| |
| − | {{tp|p=32354367|t=2020. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia |pdf=|usr=}}
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| Zeile 34: |
Zeile 39: |
| | | | |
| | | | |
| − | *'''[[Microvascular]]''' | + | *'''[[Pathobiology]]''' |
| − | * | + | |
| | + | |
| | + | *'''[[Disease Models]]''' |
| | + | |
| | + | |
| | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | *'''[[Early symptoms]]''' | | *'''[[Early symptoms]]''' |
| − | *'''[[Systemic disease, any manifestations]]'''
| |
| − | {{tp|p=32358954|t=ä. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing |pdf=|usr=}}
| |
| − | {{tp|p=32361747|t=ä. COVID-19, superinfections and antimicrobial development: What can we expect?|pdf=|usr=}}
| |
| − | {{tp|p=32188484|t=2020. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32345311|t=2020. Clinical determinants for fatality of 44,672 patients with COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Systemic disease, any manifestations]]''' |
| | | | |
| − | *'''[[ARDS]]''' | + | *'''[[Co-Infection]]''' |
| − | {{tp|p=32173725|t=ä. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32161968|t=ä. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias |pdf=|usr=}}
| + | |
| − | {{tp|p=32271373|t=ä. Predictors of refractory Coronavirus disease (COVID-19) pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32375845|t=2020. Acute respiratory failure in COVID-19: is it ?typical? ARDS?|pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32250159|t=2020. Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32357997|t=2020. Coagulopathy associated with COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32178975|t=ä. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32371557|t=2020. SARS-CoV-2 and myocardial injury: Few answers, many questions |pdf=|usr=}}
| + | |
| − | {{tp|p=32331780|t=ä. COVID-19-related cardiac involvement and potential implications for cardiothoracic imaging |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32357210|t=ä. Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32215618|t=ä. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study |pdf=|usr=}}
| + | |
| − | {{tp|p=32323704|t=2020. COVID-19 emergency in the cruise s ship: a case report of conjunctivitis |pdf=|usr=}}
| + | |
| − | {{tp|p=32266761|t=2020. Neurological manifestations in COVID19 caused by SARS-CoV?2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32354654|t=ä. Corona virus disease-19 (COVID-19) presenting as conjunctivitis: atypically high-risk during a pandemic |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| − | {{tp|p=32371006|t=ä. Diarrhea: An underestimated symptom in Coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32360055|t=ä. Suggestions for the care of patients with liver disease during the Coronavirus 2019 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32305249|t=ä. A case of COVID-19 patient with the diarrhea as initial symptom and literature review |pdf=|usr=}}
| |
| − | {{tp|p=32366282|t=2020. Liver injury in critically ill patients with COVID-19: a case series |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Kidney, urology]]==
| |
| − | *
| |
| − | *'''[[Pathobiology]]'''
| |
| | | | |
| − | *'''[[Disease Models]]''' | + | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32215622|t=ä. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]''' | + | *'''[[Kidney, urology]]''' |
| − | *
| + | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| + | |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]''' | + | *'''[[The morbid survivor]]''' |
| − | {{tp|p=32327229|t=2020. CT characteristics of patients infected with 2019 novel coronavirus: association with clinical type |pdf=|usr=}}
| + | |
| − | {{tp|p=32331781|t=ä. Ultrasound in COVID-19: a timeline of ultrasound findings in relation to CT |pdf=|usr=}}
| + | |
| − | {{tp|p=32355659|t=ä. The role of 18F-FDG PET for COVID-19 infection: myth versus reality |pdf=|usr=}}
| + | |
| − | {{tp|p=32295762|t=2020. Chest CT imaging of an early Canadian case of COVID-19 in a 28-year-old man |pdf=|usr=}}
| + | |
| − | {{tp|p=32312827|t=2020. Lung ultrasonography in a woman with COVID-19: This examination could be remote |pdf=|usr=}}
| + | |
| − | {{tp|p=32375883|t=2020. Can computed tomography be a primary tool for COVID-19 detection? Evidence appraisal through meta-analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32234724|t=2020. Lung ultrasound findings in a 64-year-old woman with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32345353|t=2020. Lung ultrasound findings in patients with COVID-19 pneumonia |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| − | {{tp|p=32360444|t=ä. Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP) |pdf=|usr=}}
| |
| − | {{tp|p=32216962|t=2020. An update on COVID-19 for the radiologist - A British society of Thoracic Imaging statement |pdf=|usr=}}
| |
| − | {{tp|p=32344166|t=ä. COVID-19 pandemic?a focused review for clinicians |pdf=|usr=}}
| |
| − | {{tp|p=32216961|t=2020. Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area |pdf=|usr=}}
| |
| − | {{tp|p=32321645|t=ä. The continuing evolution of COVID-19 imaging pathways in the UK: a British Society of Thoracic Imaging expert reference group update |pdf=|usr=}}
| |
| − | {{tp|p=32328954|t=ä. Clinical Pathway for Early Diagnosis of COVID-19: Updates from Experience to Evidence-Based Practice |pdf=|usr=}}
| |
| − | {{tp|p=32321116|t=2020. COVID-19 Diagnostic and Management Protocol for Pediatric Patients |pdf=|usr=}}
| |
| − | {{tp|p=32350002|t=2020. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline |pdf=|usr=}}
| |
| − | {{tp|p=32312828|t=2020. Clarifying the role of lung ultrasonography in COVID-19 respiratory disease |pdf=|usr=}}
| |
| − | {{tp|p=32375855|t=2020. Ethics guidelines on COVID-19 triage?an emerging international consensus |pdf=|usr=}}
| |
| − | {{tp|p=32234064|t=2020. Covid-19 in China: ten critical issues for intensive care medicine |pdf=|usr=}}
| |
| − | {{tp|p=32188482|t=2020. COVID-19 infection epidemic: the medical management strategies in Heilongjiang Province, China |pdf=|usr=}}
| |
| − | {{tp|p=32151274|t=2020. Preparing for COVID-19: early experience from an intensive care unit in Singapore |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Respiration mgmt]]''' | + | *'''[[Case reports]]''' |
| − | {{tp|p=32371555|t=2020. Utility of extracorporeal membrane oxygenation in COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32357995|t=2020. Tracheal intubation in patients with COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| − | {{tp|p=32304745|t=ä. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32161990|t=ä. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China |pdf=|usr=}}
| |
| − | {{tp|p=32328736|t=ä. No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity |pdf=|usr=}}
| |
| − | {{tp|p=32376643|t=2020. Postpartum exacerbation of antenatal COVID-19 pneumonia in 3 women |pdf=|usr=}}
| |
| − | {{tp|p=32332039|t=2020. Renin-angiotensin-aldosterone system inhibitors and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32357998|t=2020. Cardiac considerations in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32332038|t=2020. Asthma and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32264922|t=2020. COVID-19 and the RAAS?a potential role for angiotensin II?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32147731|t=ä. Diagnosis and Management of First Case of COVID-19 in Canada: Lessons applied from SARS |pdf=|usr=}}
| |
| − | {{tp|p=32227197|t=ä. A Community Transmitted Case of Severe Acute Respiratory Distress Syndrome due to SARS CoV2 in the United States |pdf=|usr=}}
| |
| − | {{tp|p=32211789|t=ä. The first locally acquired novel case of 2019-nCoV infection in a healthcare worker in the Paris area |pdf=|usr=}}
| |
| − | {{tp|p=32240285|t=ä. First Mildly Ill, Non-Hospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States ? Maricopa County, Arizona, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32332041|t=2020. SARS-CoV-2 infection in a 76-year-old man with negative results for nasopharyngeal swabs and possible nosocomial transmission |pdf=|usr=}}
| |
| − | {{tp|p=32317275|t=2020. SARS-CoV-2 infection associated with spontaneous pneumothorax |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32251842|t=ä. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital |pdf=|usr=}}
| |
| − | {{tp|p=32359867|t=ä. Impact of gender on extent of lung injury in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32362344|t=ä. Association between clinical manifestations and prognosis in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32078069|t=2020. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies |pdf=|usr=}}
| |
| − | {{tp|p=32375850|t=2020. Intensive care for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a makeshift ICU in Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32354360|t=2020. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | * | + | *'''[[Registries]]''' |
| | + | |
| | + | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| | + | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32344167|t=ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study |pdf=|usr=}}
| |
| − | {{tp|p=32305181|t=ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32360083|t=ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32306288|t=ä. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties |pdf=|usr=}}
| |
| − | {{tp|p=32277367|t=ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets |pdf=|usr=}}
| |
| − | {{tp|p=32373721|t=2020. Low dose lung radiotherapy for COVID-19 pneumonia The rationale for a cost-effective anti-inflammatory treatment |pdf=|usr=}}
| |
| − | {{tp|p=32269021|t=2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32209231|t=2020. Computers and viral diseases Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32264963|t=2020. A new clinical trial to test high-dose vitamin C in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32280433|t=ä. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model |pdf=|usr=}}
| |
| − | {{tp|p=32345336|t=2020. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | *'''[[Other routes of infection]]'''
| + | |
| − | {{tp|p=32241022|t=ä. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32297915|t=ä. Comment of the potential risks of sexual and vertical transmission of Covid-19 infection |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32315026|t=ä. Responding to the COVID-19 outbreak in Singapore: Staff Protection and Staff Temperature and Sickness Surveillance Systems |pdf=|usr=}}
| |
| − | {{tp|p=32166318|t=ä. Protecting Health Care Workers during the COVID-19 Coronavirus Outbreak ?Lessons from Taiwan s SARS response |pdf=|usr=}}
| |
| − | {{tp|p=32354653|t=ä. COVID-19 Pandemic: Survey of future use of personal protective equipment in optometric practice |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *
| + | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32371561|t=2020. Pulmonary function testing precautions in a time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32371560|t=2020. PAP therapy increases the risk of transmission of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32252508|t=2020. Sharing Our Experience of Operating an Endoscopy Unit in the Midst of a COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32371164|t=ä. RECOMMENDATIONS FOR ESSENTIAL ESOPHAGEAL PHYSIOLOGICTESTING DURING THE COVID-19 PANDEMIC |pdf=|usr=}}
| |
| − | {{tp|p=32304737|t=ä. Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32166310|t=ä. A Novel Approach for a Novel Pathogen: using a home assessment team to evaluate patients for 2019 novel coronavirus (SARS-CoV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32278082|t=ä. Challenges and issues about organising a hospital to respond to the COVID-19 outbreak: experience from a French reference centre |pdf=|usr=}}
| |
| − | {{tp|p=32330569|t=ä. Clinical microbiology laboratory adaptation to COVID-19 emergency: experience at a large teaching hospital in Rome, Italy |pdf=|usr=}}
| |
| − | {{tp|p=32312609|t=ä. Full Spectrum of Cancer Patients in SARS-CoV-2 Infection Still Being Described |pdf=|usr=}}
| |
| − | {{tp|p=32299723|t=ä. Considerations for the Treatment of Oesophageal Cancer With Radiotherapy During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32362444|t=ä. Lymphocytopenia and Radiotherapy Treatment Volumes in the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32359847|t=ä. Challenges and Consequences of COVID-19 in the Management of Anorectal Cancer: Coming Together Through Social Distancing |pdf=|usr=}}
| |
| − | {{tp|p=32354668|t=ä. Effect of COVID-19 pandemic on cancer clinician decision making: Known knowns and known unknowns |pdf=|usr=}}
| |
| − | {{tp|p=32359846|t=2020. Managing the COVID-19 Pandemic as a National Radiation Oncology Centre in Singapore |pdf=|usr=}}
| |
| − | {{tp|p=32246280|t=ä. Health services provision of 48 public tertiary dental hospitals during the COVID-19 epidemic in China |pdf=|usr=}}
| |
| − | {{tp|p=32078048|t=ä. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis |pdf=|usr=}}
| |
| − | {{tp|p=32265036|t=2020. A British Society of Thoracic Imaging statement: considerations in designing local imaging diagnostic algorithms for the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32291080|t=ä. Planning and coordination of the radiological response to the coronavirus disease 2019 (COVID-19) pandemic: the Singapore experience |pdf=|usr=}}
| |
| − | {{tp|p=32299617|t=2020. Respirators and surgical facemasks for COVID-19: implications for MRI |pdf=|usr=}}
| |
| − | {{tp|p=32235170|t=ä. Triaging Spine Surgery in the COVID-19 Era |pdf=|usr=}}
| |
| − | {{tp|p=32274425|t=2020. COVID-19: Global radiation oncology?s targeted response for pandemic preparedness |pdf=|usr=}}
| |
| − | {{tp|p=32321117|t=2020. Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance |pdf=|usr=}}
| |
| − | {{tp|p=32294673|t=2020. How should health systems prepare for the evolving COVID-19 pandemic? Reflections from the perspective of a Tertiary Cancer Center |pdf=|usr=}}
| |
| − | {{tp|p=32376644|t=2020. Confronting the COVID-19 surgery crisis: time for transformational change |pdf=|usr=}}
| |
| − | {{tp|p=32152059|t=2020. Proposed protocol to keep COVID-19 out of hospitals |pdf=|usr=}}
| |
| − | {{tp|p=32269020|t=2020. Projecting demand for critical care beds during COVID-19 outbreaks in Canada |pdf=|usr=}}
| |
| − | {{tp|p=32317277|t=2020. Redesign of a rural emergency department to prepare for the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32336679|t=2020. Optimizing provision of extracorporeal life support during the COVID-19 pandemic: practical considerations for Canadian jurisdictions |pdf=|usr=}}
| |
| − | {{tp|p=32273245|t=ä. The COVID-19 pandemic: Important considerations for contact lens practitioners |pdf=|usr=}}
| |
| − | {{tp|p=32359967|t=ä. Increased risk of ocular injury seen during lockdown due to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32336578|t=ä. Could telehealth help eye care practitioners adapt contact lens services during the COVID-19 pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32272172|t=2020. Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?|pdf=|usr=}}
| |
| − | {{tp|p=32334933|t=ä. Contact lens wear during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32305289|t=ä. No-Test Medication Abortion: A Sample Protocol for Increasing Access During a Pandemic and Beyond??? |pdf=|usr=}}
| |
| − | {{tp|p=32183864|t=2020. Safe patient transport for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32070391|t=2020. Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China |pdf=|usr=}}
| |
| − | {{tp|p=32264974|t=2020. Practice of novel method of bedside postpyloric tube placement in patients with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32345337|t=2020. Is a more aggressive COVID-19 case detection approach mitigating the burden on ICUs? Some reflections from Italy |pdf=|usr=}}
| |
| − | {{tp|p=32345343|t=2020. COVID-19: ICU delirium management during SARS-CoV-2 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32345359|t=2020. The role of telemedicine during the COVID-19 epidemic in China?experience from Shandong province |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Mental aspects of health professionals]]'''
| |
| − | {{tp|p=32246142|t=ä. Care for the psychological status of frontline medical staff fighting against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32339218|t=ä. Working schedule, sleep quality and susceptibility to COVID-19 in healthcare workers |pdf=|usr=}}
| |
| − | {{tp|p=32295761|t=2020. Mitigating the psychological effects of COVID-19 on health care workers |pdf=|usr=}}
| |
| − | {{tp|p=32375848|t=2020. Psychological stress of ICU nurses in the time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32220243|t=2020. Special attention to nurses? protection during the COVID-19 epidemic |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Mental aspects of health professionals]]''' |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32371559|t=2020. Helping children cope with the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32357996|t=2020. Health care practitioners responsibility to address intimate partner violence related to the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32299225|t=2020. Physical Distancing and Emotional Closeness Amidst COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Educational aspects of the status hygienicus]]''' | | *'''[[Educational aspects of the status hygienicus]]''' |
| − | *
| + | ---- |
| | + | |
| | + | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | *'''[[Origin of Covid19]]'''
| |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]''' | + | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32311512|t=ä. Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32266381|t=ä. PCR Assays Turned Positive in 25 Discharged COVID-19 Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32302000|t=ä. The duration of viral shedding of discharged patients with severe COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32360448|t=ä. SARS-CoV-2 positivity in a discharged COVID-19 patient: A Case report |pdf=|usr=}}
| + | |
| − | {{tp|p=32304746|t=ä. A report of three COVID-19 cases with prolonged viral RNA detection in anal swabs |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32344169|t=ä. A cluster of COVID-19 cases in a small Italian town: a successful example of contact tracing and swab collection |pdf=|usr=}}
| |
| − | {{tp|p=32344168|t=ä. Early diagnosis and rapid isolation: response to COVID-19 outbreak in Korea |pdf=|usr=}}
| |
| − | {{tp|p=32354669|t=ä. COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern Italy |pdf=|usr=}}
| |
| − | {{tp|p=32331805|t=ä. Echoes of 2009 H1N1 Influenza Pandemic in the COVID Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32144097|t=2020. What can early Canadian experience screening for COVID-19 teach us about how to prepare for a pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32269019|t=2020. Social distancing to combat COVID-19: We are all on the front line |pdf=|usr=}}
| |
| − | {{tp|p=32332040|t=2020. What can countries learn from Hong Kong s response to the COVID-19 pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32269018|t=2020. Mathematical modelling of COVID-19 transmission and mitigation strategies in the population of Ontario, Canada |pdf=|usr=}}
| |
| − | {{tp|p=32355435|t=ä. Mathematical modeling of the spread of the coronavirus disease 2019 (COVID-19) taking into account the undetected infections The case of China |pdf=|usr=}}
| |
| − | {{tp|p=32220236|t=2020. Familial cluster of COVID-19 infection from an asymptomatic |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Failure of politics and public health guidance]]''' | + | |
| − | {{tp|p=32246996|t=ä. The SARS-CoV-2 epidemic: how the Italian public is being informed |pdf=|usr=}}
| + | |
| − | {{tp|p=32292239|t=2020. Unpacking the black box: How to promote citizen engagement through government social media during the COVID-19 crisis |pdf=|usr=}}
| + | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | + | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | + | |
| | + | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| | + | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | + | ---- |
| | + | |
| | + | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | *'''[[Current state of coviki.org]]'''
| |
| − | *[[PubMed selected papers unsorted to be listed in contents topics]]
| |
| − | *[[coviki state of development]]
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32296817|t=ä. Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials |pdf=|usr=}}
| |
| − | {{tp|p=32360446|t=2020. COVID-19: don t neglect antimicrobial stewardship principles!|pdf=|usr=}}
| |
| − | {{tp|p=32058086|t=2020. Novel coronavirus: how things are in Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32366470|t=2020. Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32184199|t=2020. Working together to contain and manage COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32312831|t=2020. Who should wear a face mask? Experts weigh in on Canada s COVID-19 response |pdf=|usr=}}
| |
| − | {{tp|p=32336678|t=2020. Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32362721|t=ä. Cyberpsychology research and COVID-19 |pdf=|usr=}}
| |
| | | | |
| − | {{tp|p=32178711|t=2020. Treatment of COVID-19: old tricks for new challenges |pdf=|usr=}} | + | |
| | + | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | + | |
| | + | *'''[[from the ads]]''' |
| | + | |
| | + | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
